HRMY Expense Breakdown
Harmony Biosciences Holdings, Inc. (HRMY). Quarter ended 2026-06-30 · each product line is listed as filed.
- 2026-06-30: Rare Neurological Diseases $63.19M.
- 2025-06-30: Rare Neurological Diseases $38.15M.
Expenses by product
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization: each quarter (3 month)
| Quarter end | Rare Neurological Diseases |
|---|---|
| 2026-06-30 | $63.19M |
| 2025-06-30 | $38.15M |
Depreciation And Amortization: each quarter (3 month)
| Quarter end | Rare Neurological Diseases |
|---|---|
| 2026-06-30 | $5.97M |
| 2025-06-30 | $5.97M |
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Rare Neurological Diseases |
|---|---|
| 2026-06-30 | $17.83M |
| 2025-06-30 | $9.86M |
Research And Development Expense Excluding Share Based Compensation And In Process Research And Development Expense: each quarter (3 month)
| Quarter end | Rare Neurological Diseases |
|---|---|
| 2026-06-30 | $44.03M |
| 2025-06-30 | $33.05M |
Share-based Payment Arrangement, Expense: each quarter (3 month)
| Quarter end | Rare Neurological Diseases |
|---|---|
| 2026-06-30 | $9.58M |
| 2025-06-30 | $11.39M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |